Loading…

Bryodulcosigenin attenuates bleomycin‐induced pulmonary fibrosis via inhibiting AMPK‐mediated mesenchymal epithelial transition and oxidative stress

Fibrosis is a pathological result of a dysfunctional repair response to tissue injury and occurs in several organs, including the lungs. Bryodulcosigenin (BDG) is a cucurbitane‐type triterpene isolated from Siratia grosvenori and has clear‐cut anti‐inflammatory effects, yet its benefit of pulmonary...

Full description

Saved in:
Bibliographic Details
Published in:Phytotherapy research 2022-10, Vol.36 (10), p.3911-3923
Main Authors: Ding, Yue, Wang, Lei, Liu, Bei, Ren, Guoqing, Okubo, Ryosuke, Yu, Jing, Zhang, Chaofeng
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3265-cd99b3b1c9328d041af7e3e3c60f560669f2cab66c16761c304fe1a221f8f0ec3
cites cdi_FETCH-LOGICAL-c3265-cd99b3b1c9328d041af7e3e3c60f560669f2cab66c16761c304fe1a221f8f0ec3
container_end_page 3923
container_issue 10
container_start_page 3911
container_title Phytotherapy research
container_volume 36
creator Ding, Yue
Wang, Lei
Liu, Bei
Ren, Guoqing
Okubo, Ryosuke
Yu, Jing
Zhang, Chaofeng
description Fibrosis is a pathological result of a dysfunctional repair response to tissue injury and occurs in several organs, including the lungs. Bryodulcosigenin (BDG) is a cucurbitane‐type triterpene isolated from Siratia grosvenori and has clear‐cut anti‐inflammatory effects, yet its benefit of pulmonary fibrosis (PF) remains unclear. In this study, we investigated the protective effects of BDG (10 mg/kg/day, for 14 days) against TGF‐β1‐stimulated mouse alveolar epithelial MLE‐12 cells and bleomycin (BLM)‐induced PF mice. In vitro experiments showed that BDG could inhibit epithelial‐mesenchymal transition (EMT) and oxidative stress. In vivo experiments indicated that BDG could ameliorate BLM‐induced PF in mice as evidenced by characteristic structural changes in histopathology, increased collagen deposition and reduced survival and weight of mice. The abnormal increased expressions of TGF‐β1, p‐Smad2/3, α‐SMA, COL‐I, and NOX4 and decreased expressions for Sirt1 and p‐AMPK were improved in BDG treatment. But these beneficial effects could be eliminated by co‐treatment with Compound C (CC, a selective AMPK inhibitor). Molecular docking technology also revealed the potential of BDG to activate AMPK. In summary, AMPK activation modulated by BDG not only ameliorated TGF‐β1/Smad2/3 signaling pathways but also partially mediated the suppression effects on EMT and oxidative stress, thus mediating the anti‐fibrotic effects.
doi_str_mv 10.1002/ptr.7535
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2686058402</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2723716431</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3265-cd99b3b1c9328d041af7e3e3c60f560669f2cab66c16761c304fe1a221f8f0ec3</originalsourceid><addsrcrecordid>eNp1kc1qFzEUxYMo-LcVfISAGzdT8zGTmVnW4hdWWqSCu5BJbvpPySRjkqnOzkdw2efzSUxtQRBc3bv4nXMv5yD0jJIjSgh7uZR01He8e4B2lIxjQ7ueP0Q7Mna0aenw5TF6kvMVIWRkpN2hm1dpi2b1OmZ3CcEFrEqBsKoCGU8e4rxpF379-OmCWTUYvKx-jkGlDVs3parK-Nop7MLeTa64cImPP55_qIIZjKsuBs-QIej9NiuPYXFlD97VtSQVclXEejIYHL87o4q7BpxLgpwP0SOrfIan9_MAfX7z-uLkXXN69vb9yfFpozkTXaPNOE58onrkbDCkpcr2wIFrQWwniBCjZVpNQmgqekE1J60FqhijdrAEND9AL-58lxS_rpCLnF3W4L0KENcsmRgE6YaWsIo-_we9imsK9TvJesZ7KlpO_xrqmk5OYOWS3FwDk5TI24pkrUjeVlTR5g795jxs_-Xk-cWnP_xvCLuY7A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2723716431</pqid></control><display><type>article</type><title>Bryodulcosigenin attenuates bleomycin‐induced pulmonary fibrosis via inhibiting AMPK‐mediated mesenchymal epithelial transition and oxidative stress</title><source>Wiley</source><creator>Ding, Yue ; Wang, Lei ; Liu, Bei ; Ren, Guoqing ; Okubo, Ryosuke ; Yu, Jing ; Zhang, Chaofeng</creator><creatorcontrib>Ding, Yue ; Wang, Lei ; Liu, Bei ; Ren, Guoqing ; Okubo, Ryosuke ; Yu, Jing ; Zhang, Chaofeng</creatorcontrib><description>Fibrosis is a pathological result of a dysfunctional repair response to tissue injury and occurs in several organs, including the lungs. Bryodulcosigenin (BDG) is a cucurbitane‐type triterpene isolated from Siratia grosvenori and has clear‐cut anti‐inflammatory effects, yet its benefit of pulmonary fibrosis (PF) remains unclear. In this study, we investigated the protective effects of BDG (10 mg/kg/day, for 14 days) against TGF‐β1‐stimulated mouse alveolar epithelial MLE‐12 cells and bleomycin (BLM)‐induced PF mice. In vitro experiments showed that BDG could inhibit epithelial‐mesenchymal transition (EMT) and oxidative stress. In vivo experiments indicated that BDG could ameliorate BLM‐induced PF in mice as evidenced by characteristic structural changes in histopathology, increased collagen deposition and reduced survival and weight of mice. The abnormal increased expressions of TGF‐β1, p‐Smad2/3, α‐SMA, COL‐I, and NOX4 and decreased expressions for Sirt1 and p‐AMPK were improved in BDG treatment. But these beneficial effects could be eliminated by co‐treatment with Compound C (CC, a selective AMPK inhibitor). Molecular docking technology also revealed the potential of BDG to activate AMPK. In summary, AMPK activation modulated by BDG not only ameliorated TGF‐β1/Smad2/3 signaling pathways but also partially mediated the suppression effects on EMT and oxidative stress, thus mediating the anti‐fibrotic effects.</description><identifier>ISSN: 0951-418X</identifier><identifier>EISSN: 1099-1573</identifier><identifier>DOI: 10.1002/ptr.7535</identifier><language>eng</language><publisher>Chichester, UK: John Wiley &amp; Sons, Ltd</publisher><subject>Alveoli ; AMPK activation ; Bleomycin ; bryodulcosigenin ; Collagen ; epithelial–mesenchymal transition ; Fibrosis ; Histopathology ; Inflammation ; Lung diseases ; Mesenchyme ; Molecular docking ; NOX4 protein ; Oxidative stress ; Pulmonary fibrosis ; SIRT1 protein ; Smad2 protein</subject><ispartof>Phytotherapy research, 2022-10, Vol.36 (10), p.3911-3923</ispartof><rights>2022 John Wiley &amp; Sons Ltd.</rights><rights>2022 John Wiley &amp; Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3265-cd99b3b1c9328d041af7e3e3c60f560669f2cab66c16761c304fe1a221f8f0ec3</citedby><cites>FETCH-LOGICAL-c3265-cd99b3b1c9328d041af7e3e3c60f560669f2cab66c16761c304fe1a221f8f0ec3</cites><orcidid>0000-0002-1504-305X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Ding, Yue</creatorcontrib><creatorcontrib>Wang, Lei</creatorcontrib><creatorcontrib>Liu, Bei</creatorcontrib><creatorcontrib>Ren, Guoqing</creatorcontrib><creatorcontrib>Okubo, Ryosuke</creatorcontrib><creatorcontrib>Yu, Jing</creatorcontrib><creatorcontrib>Zhang, Chaofeng</creatorcontrib><title>Bryodulcosigenin attenuates bleomycin‐induced pulmonary fibrosis via inhibiting AMPK‐mediated mesenchymal epithelial transition and oxidative stress</title><title>Phytotherapy research</title><description>Fibrosis is a pathological result of a dysfunctional repair response to tissue injury and occurs in several organs, including the lungs. Bryodulcosigenin (BDG) is a cucurbitane‐type triterpene isolated from Siratia grosvenori and has clear‐cut anti‐inflammatory effects, yet its benefit of pulmonary fibrosis (PF) remains unclear. In this study, we investigated the protective effects of BDG (10 mg/kg/day, for 14 days) against TGF‐β1‐stimulated mouse alveolar epithelial MLE‐12 cells and bleomycin (BLM)‐induced PF mice. In vitro experiments showed that BDG could inhibit epithelial‐mesenchymal transition (EMT) and oxidative stress. In vivo experiments indicated that BDG could ameliorate BLM‐induced PF in mice as evidenced by characteristic structural changes in histopathology, increased collagen deposition and reduced survival and weight of mice. The abnormal increased expressions of TGF‐β1, p‐Smad2/3, α‐SMA, COL‐I, and NOX4 and decreased expressions for Sirt1 and p‐AMPK were improved in BDG treatment. But these beneficial effects could be eliminated by co‐treatment with Compound C (CC, a selective AMPK inhibitor). Molecular docking technology also revealed the potential of BDG to activate AMPK. In summary, AMPK activation modulated by BDG not only ameliorated TGF‐β1/Smad2/3 signaling pathways but also partially mediated the suppression effects on EMT and oxidative stress, thus mediating the anti‐fibrotic effects.</description><subject>Alveoli</subject><subject>AMPK activation</subject><subject>Bleomycin</subject><subject>bryodulcosigenin</subject><subject>Collagen</subject><subject>epithelial–mesenchymal transition</subject><subject>Fibrosis</subject><subject>Histopathology</subject><subject>Inflammation</subject><subject>Lung diseases</subject><subject>Mesenchyme</subject><subject>Molecular docking</subject><subject>NOX4 protein</subject><subject>Oxidative stress</subject><subject>Pulmonary fibrosis</subject><subject>SIRT1 protein</subject><subject>Smad2 protein</subject><issn>0951-418X</issn><issn>1099-1573</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp1kc1qFzEUxYMo-LcVfISAGzdT8zGTmVnW4hdWWqSCu5BJbvpPySRjkqnOzkdw2efzSUxtQRBc3bv4nXMv5yD0jJIjSgh7uZR01He8e4B2lIxjQ7ueP0Q7Mna0aenw5TF6kvMVIWRkpN2hm1dpi2b1OmZ3CcEFrEqBsKoCGU8e4rxpF379-OmCWTUYvKx-jkGlDVs3parK-Nop7MLeTa64cImPP55_qIIZjKsuBs-QIej9NiuPYXFlD97VtSQVclXEejIYHL87o4q7BpxLgpwP0SOrfIan9_MAfX7z-uLkXXN69vb9yfFpozkTXaPNOE58onrkbDCkpcr2wIFrQWwniBCjZVpNQmgqekE1J60FqhijdrAEND9AL-58lxS_rpCLnF3W4L0KENcsmRgE6YaWsIo-_we9imsK9TvJesZ7KlpO_xrqmk5OYOWS3FwDk5TI24pkrUjeVlTR5g795jxs_-Xk-cWnP_xvCLuY7A</recordid><startdate>202210</startdate><enddate>202210</enddate><creator>Ding, Yue</creator><creator>Wang, Lei</creator><creator>Liu, Bei</creator><creator>Ren, Guoqing</creator><creator>Okubo, Ryosuke</creator><creator>Yu, Jing</creator><creator>Zhang, Chaofeng</creator><general>John Wiley &amp; Sons, Ltd</general><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1504-305X</orcidid></search><sort><creationdate>202210</creationdate><title>Bryodulcosigenin attenuates bleomycin‐induced pulmonary fibrosis via inhibiting AMPK‐mediated mesenchymal epithelial transition and oxidative stress</title><author>Ding, Yue ; Wang, Lei ; Liu, Bei ; Ren, Guoqing ; Okubo, Ryosuke ; Yu, Jing ; Zhang, Chaofeng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3265-cd99b3b1c9328d041af7e3e3c60f560669f2cab66c16761c304fe1a221f8f0ec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Alveoli</topic><topic>AMPK activation</topic><topic>Bleomycin</topic><topic>bryodulcosigenin</topic><topic>Collagen</topic><topic>epithelial–mesenchymal transition</topic><topic>Fibrosis</topic><topic>Histopathology</topic><topic>Inflammation</topic><topic>Lung diseases</topic><topic>Mesenchyme</topic><topic>Molecular docking</topic><topic>NOX4 protein</topic><topic>Oxidative stress</topic><topic>Pulmonary fibrosis</topic><topic>SIRT1 protein</topic><topic>Smad2 protein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ding, Yue</creatorcontrib><creatorcontrib>Wang, Lei</creatorcontrib><creatorcontrib>Liu, Bei</creatorcontrib><creatorcontrib>Ren, Guoqing</creatorcontrib><creatorcontrib>Okubo, Ryosuke</creatorcontrib><creatorcontrib>Yu, Jing</creatorcontrib><creatorcontrib>Zhang, Chaofeng</creatorcontrib><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Phytotherapy research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ding, Yue</au><au>Wang, Lei</au><au>Liu, Bei</au><au>Ren, Guoqing</au><au>Okubo, Ryosuke</au><au>Yu, Jing</au><au>Zhang, Chaofeng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bryodulcosigenin attenuates bleomycin‐induced pulmonary fibrosis via inhibiting AMPK‐mediated mesenchymal epithelial transition and oxidative stress</atitle><jtitle>Phytotherapy research</jtitle><date>2022-10</date><risdate>2022</risdate><volume>36</volume><issue>10</issue><spage>3911</spage><epage>3923</epage><pages>3911-3923</pages><issn>0951-418X</issn><eissn>1099-1573</eissn><abstract>Fibrosis is a pathological result of a dysfunctional repair response to tissue injury and occurs in several organs, including the lungs. Bryodulcosigenin (BDG) is a cucurbitane‐type triterpene isolated from Siratia grosvenori and has clear‐cut anti‐inflammatory effects, yet its benefit of pulmonary fibrosis (PF) remains unclear. In this study, we investigated the protective effects of BDG (10 mg/kg/day, for 14 days) against TGF‐β1‐stimulated mouse alveolar epithelial MLE‐12 cells and bleomycin (BLM)‐induced PF mice. In vitro experiments showed that BDG could inhibit epithelial‐mesenchymal transition (EMT) and oxidative stress. In vivo experiments indicated that BDG could ameliorate BLM‐induced PF in mice as evidenced by characteristic structural changes in histopathology, increased collagen deposition and reduced survival and weight of mice. The abnormal increased expressions of TGF‐β1, p‐Smad2/3, α‐SMA, COL‐I, and NOX4 and decreased expressions for Sirt1 and p‐AMPK were improved in BDG treatment. But these beneficial effects could be eliminated by co‐treatment with Compound C (CC, a selective AMPK inhibitor). Molecular docking technology also revealed the potential of BDG to activate AMPK. In summary, AMPK activation modulated by BDG not only ameliorated TGF‐β1/Smad2/3 signaling pathways but also partially mediated the suppression effects on EMT and oxidative stress, thus mediating the anti‐fibrotic effects.</abstract><cop>Chichester, UK</cop><pub>John Wiley &amp; Sons, Ltd</pub><doi>10.1002/ptr.7535</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-1504-305X</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0951-418X
ispartof Phytotherapy research, 2022-10, Vol.36 (10), p.3911-3923
issn 0951-418X
1099-1573
language eng
recordid cdi_proquest_miscellaneous_2686058402
source Wiley
subjects Alveoli
AMPK activation
Bleomycin
bryodulcosigenin
Collagen
epithelial–mesenchymal transition
Fibrosis
Histopathology
Inflammation
Lung diseases
Mesenchyme
Molecular docking
NOX4 protein
Oxidative stress
Pulmonary fibrosis
SIRT1 protein
Smad2 protein
title Bryodulcosigenin attenuates bleomycin‐induced pulmonary fibrosis via inhibiting AMPK‐mediated mesenchymal epithelial transition and oxidative stress
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T08%3A09%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bryodulcosigenin%20attenuates%20bleomycin%E2%80%90induced%20pulmonary%20fibrosis%20via%20inhibiting%20AMPK%E2%80%90mediated%20mesenchymal%20epithelial%20transition%20and%20oxidative%20stress&rft.jtitle=Phytotherapy%20research&rft.au=Ding,%20Yue&rft.date=2022-10&rft.volume=36&rft.issue=10&rft.spage=3911&rft.epage=3923&rft.pages=3911-3923&rft.issn=0951-418X&rft.eissn=1099-1573&rft_id=info:doi/10.1002/ptr.7535&rft_dat=%3Cproquest_cross%3E2723716431%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3265-cd99b3b1c9328d041af7e3e3c60f560669f2cab66c16761c304fe1a221f8f0ec3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2723716431&rft_id=info:pmid/&rfr_iscdi=true